Abstract:Heat shock protein 90 (HSP90) has emerged as an important target in cancer treatment because many of its clients are crucial in malignant transformation. HSP90 inhibitors such as antibiotic anismycin Geldanamycin and its derivatives 17-AAG promote degradation of client proteins. Several preclinical observations have made HSP90 inhibitors attractive drugs to the treatment of cancer. First, HSP90 inhibitors may provide a broader and effective anticancer therapy. Second, HSP90 in tumor cells was shown to exhibit much higher affinity for its inhibitors. HSP90 inhibitors such as 17-AAG and 17-DMAG are currently used targeting a variety of tumors in clinical trials. The TGFβ signaling pathway represents a major tumor suppressor pathway in normal epithelial cells, and paradoxically, it also acts as a significant promoter of tumor progression, invasion and metastasis in carcinomas. Since tumors are often detected in late stages, inhibition of TGFβ signaling pathway may be beneficiary to cancer patients. Several attempts in the past several years have highlighted the potential of blocking TGFβ responses in tumors by using soluble TGFβ receptors or competitive small molecules targeting the TGFβ receptors in anti-cancer therapy. Notably, the toxicity of TGFβ inhibition is well tolerated in mouse models, suggesting the strong potential of anti-TGFβ therapeutics in cancer. Our recent identification that TGFβ receptors are client proteins of HSP90 provides novel insights into the potential of HSP90 inhibitors in anti-cancer therapies. Objective: (1) To elucidate the molecular mechanisms underlying essential role of HSP90 in controlling TGFβ signaling in normal and cancer cells; (2) To explore the potential of HSP90 inhibitors as anti-metastasis therapeutics in breast cancer. Methods: Using a proteomic approach, we found an association between HSP90 and TGFβ receptors (both TβRI and TβRII). Further TβR-HSP90 interaction, TβR turnover and Smad2 phosphorylation were carried out using immunoprecipitation and western blotting. Dosage and duration of treatment with HSP90 inhibitors GA, 17-AAG, and Ridicicol were initially established by evaluating the blockade of TGFβ-induced Smad2 phosphorylation. Effect of HSP90 inhibitors and HSP90 siRNAs on the expression of TGFβ target gene transcription will be assessed by real-time RT-PCR. Cell proliferation was assayed by 3H-thymidine incorporation, and cell invasiveness was done in BD Matrigel Invasion Chambers in MDA-MB-231 breast carcinoma cells. Results: Using biochemical assays, we confirmed that TGFβ receptors (both TβRI and TβRII) physically associated with HSP90 proteins in a variety of normal and cancer cells. We next found that inhibition of HSP90 functions by several HSP90 inhibitors can promote the rapid turnover of TGFβ receptors in a ubiquitination/proteasome-dependent manner. Consequently, HSP90 inhibitors inhibit TGFβ-mediated phosphorylation of tumor suppressors SMAD2 and SMAD3, and block TGFβ-dependent transcription of genes such as MMP9. At the cellular level, HSP90 inhibitors led to the blockade of TGFβ-induced invasiveness of MDA-MB-231 breast carcinoma cells. Conclusion: We have identified HSP90 inhibitors as potential drugs blocking TGFβ functions. This study should help to understand the mechanisms of TGFβ and HSP90 interplay in progression of human cancers. Our study will also provide invaluable information on the use of HSP90 inhibitors for the treatment of human cancers.

Inhibition of Gastric Tumor Growth by a Novel Hsp90 Inhibitor

Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response.

Discovery of Second Generation Heat Shock Protein 110 (HSP110) Inhibitors for Potential Treatment of Colorectal Cancer

Inhibitors of the HSP90 Molecular Chaperone: Current Status

Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Novel Tetrahydropyrido[4,3-d]pyrimidines As Potent Inhibitors of Chaperone Heat Shock Protein 90

Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

QS288. Potent Blockade of TGF-β Signaling by HSP90 Inhibitors

Y-632 Inhibits Heat Shock Protein 90 (hsp90) Function by Disrupting the Interaction Between Hsp90 and Hsp70/Hsp90 Organizing Protein, and Exerts Antitumor Activity in Vitro and in Vivo

Study on the Effect of HSP90 Inhibitor IPI-504 on Gastric Cancer Cells and Its Stem Cell Like Cells

Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (hsp90) and Cell Division Cycle 37 As Orally Active Inhibitors for the Treatment of Colorectal Cancer.

X66, a Novel N-terminal Heat Shock Protein 90 Inhibitor, Exerts Antitumor Effects Without Induction of Heat Shock Response

AT-533, a Novel Hsp90 Inhibitor, Inhibits Breast Cancer Growth and HIF-1α/VEGF/VEGFR-2-mediated Angiogenesis in Vitro and in Vivo.

Discovery of Potent N-(isoxazol-5-yl)amides As HSP90 Inhibitors.

Novel Hsp90 Inhibitor FW-04-806 Displays Potent Antitumor Effects in HER2-positive Breast Cancer Cells As a Single Agent or in Combination with Lapatinib

Anti-tumor Selectivity of a Novel Tubulin and HSP90 Dual-Targeting Inhibitor in Non-Small Cell Lung Cancer Models.

A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects

Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling

Design, Synthesis, and Biological Evaluation of Novel Dual Inhibitors of Heat Shock Protein 90/mammalian Target of Rapamycin (hsp90/mtor) Against Bladder Cancer Cells.

RNA Interference-Mediated Silencing of the Hsp70 Gene Inhibits Human Gastric Cancer Cell Growth and Induces Apoptosis in Vitro and in Vivo

Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.